Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, a novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health.

ARINA-1 has a strong track record of safety and efficacy. A small group of subjects have a combined 25 patient years of experience on the therapy. This track record of safety is supported by successful toxicology studies. ARINA-1 is poised to start clinical trials in chronic inflammatory airways diseases, including non-cystic fibrosis (CF) bronchiectasis and chronic obstructive pulmonary disease (COPD).